Table 1 Demographic, clinical, and laboratory characteristics of patients in the TAK >40 and TAK ≤40 groups

Onset age (IQR)

56 (48–62)

23 (20–28)

Female, n (%)

19 (95)

21 (91)

1.00

HLA-B52, n (%)

7 (47) , n = 15

11 (65), n = 17

0.48

BMI, kg/m² (IQR)

21.9 (20.2–26.2)

21.2 (18.9–22.7)

0.55

Family history

1 (5)

0 (0)

0.47

Smoking

5 (25)

4 (17)

0.71

 DM

2 (10)

2 (9)

1.00

 CKD

0 (0)

2 (9)

0.49

 IBD

1 (5)

2 (9)

1.00

 PG

1 (5)

1 (4)

1.00

 Type I

5 (25)

5 (22)

1.00

 Type IIa

2 (10)

3 (13)

1.00

 Type IIb

3 (15)

4 (17)

1.00

 Type IV

1 (5)

0 (0)

0.47

 Type V

9 (45)

11 (48)

1.00

Fever

11 (55)

14 (61)

0.76

Malaise

10 (50)

12 (52)

1.00

Headache

5 (25)

12 (52)

0.118

Dizziness

0 (0)

5 (22)

0.051

Orthostatic hypotension

2 (10)

10 (43)

0.019*

Ophthalmic symptoms

1 (5)

4 (17)

0.35

Carotid bruit

7 (35)

16 (70)

0.034*

Cervical pain

4 (20)

6 (26)

0.73

Discrepancy of blood pressure

10 (50)

11 (48)

1.00

Upper limb pain

4 (20)

9 (39)

0.20

Pulselessness

4 (20)

6 (26)

0.73

Chest pain

0 (0)

6 (26)

0.023*

Abdominal bruit

6 (30)

6 (26)

1.00

Arthralgia

5 (25)

6 (26)

1.00

Aortic valve regurgitation

5 (25)

7 (30)

0.74

WBC, ×103/μL (normal range 3.5–9.8) (IQR)

9.4 (7.1–11.7), n = 20

8.2 (6.6–10.3), n = 23

0.56

Hb, g/dL (normal range11.3–17.6) (IQR)

12.4 (10.1–13.2), n = 20

10.8 (9.4–12.0), n = 23

0.054

Plt × 104/μL, (normal range 13.0–36.9) (IQR)

29.3 (23.4–38.2), n = 20

35.1 (25.1–47.0), n = 23

0.28

CRP, mg/dL (normal range <0.14) (IQR)

4.2 (0.5–9.0), n = 20

7.0 (0.6–9.6), n = 23

0.62

ESR, mm/h, (normal range <15) (IQR)

75 (32–91), n = 18

77 (27–106), n = 17

0.74

Alb, g/dL, (normal range 3.8–5.2) (IQR)

3.7 (3.1–4.1), n = 19

3.6 (3.2–4.3), n = 21

0.95

IgG, mg/dL, (normal range 870–1700) (IQR)

1410 (1100–1670), n = 17

1660 (1190–2190), n = 22

0.33